Research & Development
A Meaningful Milestone in the Scientific Development of C60 MD
A completed 90-day safety study conducted by Taipei Medical University provides important preclinical support for the continued development of C60-Ellagic acid and helps strengthen the scientific foundation behind C60 MD.
Key Highlights
- A 90-day oral safety study has been completed
- The study was conducted by Taipei Medical University
- The research included both male and female rats
- No test-article-related mortality was observed during the study period
- No clear adverse effects on body weight were reported
- In the major organs evaluated, no test-article-related toxic changes were identified
- Under the conditions of this study, the reported no-observed-adverse-effect level (NOAEL) was at least 500 mg/kg body weight/day
A More Credible Scientific Foundation
As interest in C60 continues to grow, so do expectations for credible research and transparent scientific evaluation.
At C60 MD, we believe meaningful progress comes not only from innovation itself, but also from rigorous validation, continued research, and respect for the scientific process. This latest study is a clear reflection of that commitment.
This 90-day safety study, conducted by Taipei Medical University, one of Taiwan’s leading academic and medical institutions, marks an important step forward in the continued development of C60-Ellagic acid.
Study Findings
According to the final report, the C60-Ellagic acid formulation demonstrated good tolerability under the conditions of the study.
No test-article-related mortality was observed during the study period, and no clear adverse effects on body weight were reported. In addition, no test-article-related toxic changes were identified in the major organs evaluated, including the liver, kidney, brain, and heart.
The report also stated that, in this animal model, the no-observed-adverse-effect level (NOAEL) was at least 500 mg/kg body weight/day.
Why This Study Matters
Safety evaluation is an essential part of any product’s long-term and responsible development.
This study not only adds meaningful preclinical safety data to support the continued development of C60 MD, but also further strengthens the scientific foundation behind it. Just as importantly, it reflects a research approach grounded in care, rigor, and accountability.
For C60 MD, this milestone represents more than the completion of a single report. It is an important step forward in building trust through science.
Further Reading
Readers interested in learning more about the study and its supporting data may refer to the full report for additional background on the research design and methodology. (achievement-report-on-a-90-day-sub-chronic-oral-toxicity-study-program.pdf)
Important Note: This article is based on a summary of findings from a preclinical animal toxicity study conducted in rats. It does not establish human efficacy and should not be interpreted as a medical claim.
Additional Clinical Trials
UC San Diego Department
of Neurosciences
The trial topic: Parkinson
University of Pittsburgh
Medical Center
The trial topic: about cancers
Western University of
Health Sciences
The trial topic: Alzheimer’s & Anti-viral
Patents
(Waiting for Toxicity Test results to submit the report to FDA)
On Going Projects
Toxicity Tests: Western University: Category III safety
Genotoxicity 3:
Trial time: 3~4 months
Toxicity Trial: for 90 days
Trial Duration: 6 months
Teratogenic fetal test: 6 months trial time
Lab tests started in Dec. 2022
References
Akhtar MJ, Ahamed M, Alhadlaq HA, and Alshamsan A. Mechanism of ROS scavenging and antioxidant signaling by redox metallic and fullerene nanomaterials: Potential implications in ROS associated degenerative disorders. (2017) Biochimica et Biophysica Acta 1861, 802–813.
http://dx.doi.org/10.1016/j.bbagen.2017.01.018
Baati T, Bourasset F, Gharbi N, Njim L, Abderrabba M, Kerkeni A, Szwarc H, Moussa F. The prolongation of the lifespan of rats by repeated oral administration of [60]fullerene. (2012) Biomaterials 33, 4936 – 4946.
http://dx.doi.org/10.1016/j.biomaterials.2012.03.036
Barzegar A, Mousavi SJ, Hamidi H, Sadeghi M. 2D-QSAR study of fullerene nanostructure derivatives as potent HIV-1 protease inhibitors (2017) Physica E 93, 324–331.
http://dx.doi.org/10.1016/j.physe.2017.06.016
Dellinger A, Zhou Z, Norton SK, Lenk R, Conrad D, Kepley CL. Uptake and distribution of fullerenes in human mast cells. (2010) Nanomedicine: Nanotechnology, Biology, and Medicine 6, 575–582.
http://dx.doi.org/10.1016/j.nano.2010.01.008
Dellinger AL, Cunin P, Lee D, Kung AL, Brooks DB, Zhou Z., et al. Inhibition of Inflammatory Arthritis Using Fullerene Nanomaterials (2015) PLoS ONE 10(4): e0126290.
http://dx.doi.org/10.1371/journal.pone.0126290
References
Di Felice G, Colombo P. Nanoparticle–allergen complexes for allergen immunotherapy. (2017) International Journal of Nanomedicine, 12, 4493–4504.
http://dx.doi.org/10.2147/IJN.S134630
Dordevic A, Radmanovac D, Mertelj A, Rakočević Z, Seke M, Ičević I, and Injac R. Distribution of Fullerenol nanoparticles in human serum. (2011) Euroanalysis, 16th European Conference on Analytical Chemistry. https://www.researchgate.net/publication/267981750_DISTRIBUTION_OF_FULLERENOL_NANOPARTICLES_IN_HUMAN_SERUM
Geitner NK, Zhao W, Ding F, Chen W, and Wiesner MR. Mechanistic Insights from Discrete Molecular Dynamics Simulations of Pesticide−Nanoparticle Interactions. (2017) Environ. Sci. Technol. 51, 8396−8404.
http://dx.doi.org/10.1021/acs.est.7b01674
Krokosz A, Grebowski J, Rodacka A, Pasternak B, Puchala M. The effect of fullerol C60(OH)30 on the alcohol dehydrogenase activity irradiated with X-rays. (2014) Radiation Physics and Chemistry 97, 102–106. http://dx.doi.org/10.1016/j.radphyschem.2013.11.009
References
Li W, Li N, Sui B, and Yang D. Anti‑aging effect of fullerol on skin aging through derived stem cells in a mouse model. (2017) Experimental and Therapeutic Medicine, 14: 5045-5050.
http://dx.doi.org/10.3892/etm.2017.5163
Liu Q, Jin L, Mahon BH, Chordia MD, Shen FH, and Li X. A novel treatment of neuroinflammation against low back pain by soluble fullerol nanoparticles. Spine (Phila Pa 1976). (2013) 38(17): 1443–1451.
http://dx.doi.org/10.1097/BRS.0b013e31828fc6b7
Mamontova TV, Vesnina LE, Mikityuk MV, Bobrova NA, Kutsenko LA, Gordinskaya IL, and Kaidashev IP. Fullerene C60 Inhibits Free-Radical and Destructive Processes in Connective Tissue under Adjuvant Arthritis in Rats. (2016) International J. of Physiology and Pathophysiology, 7(2): 119-126.
http://europepmc.org/abstract/med/26387164
Nedzvetsky V, Andrievsky G, Chachibaia T, and Tykhomyrov A. Differences in Antioxidant/Protective Efficacy of Hydrated C60 Fullerene Nanostructures in Liver and Brain of Rats with Streptozotocin-Induced Diabetes. (2012) J Diabetes Metabolism, 3:8.
http://dx.doi.org/10.4172/2155-6156.1000215
References
Spesia MB, Milanesio ME, and Durantini EN. Fullerene Derivatives in Photodynamic Inactivation of Microorganisms. (2017) Nanostructures for Antimicrobial Therapy, Chapter 18, 413-433.
https://doi.org/10.1016/B978-0-323-46152-8.00018-4
Stankov K, Borisev I, Kojic V, Rutonjski L, Bogdanovic G, and Djordjevic A. Modification of Antioxidative and Antiapoptotic Genes Expression in irradiated K562 Cells Upon Fullerenol C60(OH)24 Nanoparticle Treatment. (2012) J. of Nanosci and Nanotechn., 12, 1–9.
http://dx.doi.org/10.1166/jnn.2012.6847
Tsumoto H, Kawahara S, Fujisawa Y, Suzuki T, Nakagawa H, Kohda K, et al. Syntheses of water-soluble [60]fullerene derivatives and their enhancing effect on neurite outgrowth in NGF-treated PC12 cells. (2010) Bioorg Med Chem Lett, 20(6):1948e52.
http://dx.doi.org/10.1016/j.bmcl.2010.01.142
Vani JR, Mohammadi MT, Foroshani MS, Jafari M. Polyhydroxylated fullerene nanoparticles attenuate brain infarction and oxidative stress in rat model of ischemic stroke. (2016) EXCLI Journal 15, 378-390.
http://dx.doi.org/10.17179/excli2016-309